SAN CARLOS, Calif. - Allakos Inc . (NASDAQ:ALLK), a clinical-stage biotechnology company with a market capitalization of $108 million, announced today that it will halt the development of its drug ...
Research conducted by an international team and led by biologists at the University of Kentucky has found that the ability to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback